These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 2436687)
1. Kinetics of inhibition of human plasma kallikrein by a site-specific modified inhibitor Arg15-aprotinin: evaluation using a microplate system and comparison with other proteases. Scott CF; Wenzel HR; Tschesche HR; Colman RW Blood; 1987 May; 69(5):1431-6. PubMed ID: 2436687 [TBL] [Abstract][Full Text] [Related]
2. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. Tans G; Janssen-Claessen T; Rosing J; Griffin JH Eur J Biochem; 1987 May; 164(3):637-42. PubMed ID: 3552674 [TBL] [Abstract][Full Text] [Related]
3. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates. McRae BJ; Kurachi K; Heimark RL; Fujikawa K; Davie EW; Powers JC Biochemistry; 1981 Dec; 20(25):7196-206. PubMed ID: 6976185 [TBL] [Abstract][Full Text] [Related]
4. Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display. Dennis MS; Herzka A; Lazarus RA J Biol Chem; 1995 Oct; 270(43):25411-7. PubMed ID: 7592708 [TBL] [Abstract][Full Text] [Related]
5. Alpha 1-antitrypsin-Pittsburgh: a potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. Scott CF; Carrell RW; Glaser CB; Lewis JH; Colman RW Trans Assoc Am Physicians; 1985; 98():344-51. PubMed ID: 3879844 [TBL] [Abstract][Full Text] [Related]
6. Recombinant alpha 1-antitrypsin Pittsburgh (Met 358----Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment. Schapira M; Ramus MA; Jallat S; Carvallo D; Courtney M J Clin Invest; 1986 Feb; 77(2):635-7. PubMed ID: 3484756 [TBL] [Abstract][Full Text] [Related]
7. S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin. Vadivel K; Kumar Y; Ogueli GI; Ponnuraj SM; Wongkongkathep P; Loo JA; Bajaj MS; Bajaj SP J Thromb Haemost; 2016 Dec; 14(12):2509-2523. PubMed ID: 27797450 [TBL] [Abstract][Full Text] [Related]
8. Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system. Berrettini M; Schleef RR; España F; Loskutoff DJ; Griffin JH J Biol Chem; 1989 Jul; 264(20):11738-43. PubMed ID: 2787318 [TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Hitomi Y; Ikari N; Fujii S Haemostasis; 1985; 15(3):164-8. PubMed ID: 3161808 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of aprotinin and gabexate mesilate on human plasma kallikrein. Nakahara M Arzneimittelforschung; 1983; 33(7):969-71. PubMed ID: 6194800 [TBL] [Abstract][Full Text] [Related]
12. Human plasma prekallikrein. Immunoaffinity purification and activation to alpha- and beta-kallikrein. Burger D; Schleuning WD; Schapira M J Biol Chem; 1986 Jan; 261(1):324-7. PubMed ID: 2416749 [TBL] [Abstract][Full Text] [Related]
13. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates. Cho K; Tanaka T; Cook RR; Kisiel W; Fujikawa K; Kurachi K; Powers JC Biochemistry; 1984 Feb; 23(4):644-50. PubMed ID: 6370301 [TBL] [Abstract][Full Text] [Related]
14. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Meijers JC; Kanters DH; Vlooswijk RA; van Erp HE; Hessing M; Bouma BN Biochemistry; 1988 Jun; 27(12):4231-7. PubMed ID: 2844223 [TBL] [Abstract][Full Text] [Related]
15. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition. Derechin VM; Blinder MA; Tollefsen DM J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609 [TBL] [Abstract][Full Text] [Related]
16. Development of plasma kallikrein selective inhibitors. Okada Y; Tsuda Y; Tada M; Wanaka K; Hijikata-Okunomiya A; Okamoto U; Okamoto S Biopolymers; 1999; 51(1):41-50. PubMed ID: 10380351 [TBL] [Abstract][Full Text] [Related]
17. [Effect of covalent binding of aprotinin with a polysaccharide carrier on its inhibition of kallikrein from human plasma, porcine pancreatic kallikrein and trypsin]. Larionova NI; Makevnina LG; Nartikova VF; Paskhina TS Biokhimiia; 1987 May; 52(5):825-31. PubMed ID: 2439135 [TBL] [Abstract][Full Text] [Related]
18. A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. Miles LA; Greengard JS; Griffin JH Thromb Res; 1983 Feb; 29(4):407-17. PubMed ID: 6344314 [TBL] [Abstract][Full Text] [Related]
19. Effect of heparin on the inhibition of the contact system enzymes. Colman RW; Scott CF; Pixley RA; de la Cadena RA Ann N Y Acad Sci; 1989; 556():95-103. PubMed ID: 2786690 [TBL] [Abstract][Full Text] [Related]